Article Versions Notes

Barashi NS, Li T, Angappulige DH, Zhang B, O’Gorman H, Nottingham CU, Shetty AS, Ippolito JE, Andriole GL, Mahajan NP, et al. Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development. Cancers. 2024; 16(1):213. https://doi.org/10.3390/cancers16010213

Barashi, Nimrod S., Tiandao Li, Duminduni H. Angappulige, Bo Zhang, Harry O’Gorman, Charles U. Nottingham, Anup S. Shetty, Joseph E. Ippolito, Gerald L. Andriole, Nupam P. Mahajan, and et al. 2024. "Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development" Cancers 16, no. 1: 213. https://doi.org/10.3390/cancers16010213

Barashi, N. S., Li, T., Angappulige, D. H., Zhang, B., O’Gorman, H., Nottingham, C. U., Shetty, A. S., Ippolito, J. E., Andriole, G. L., Mahajan, N. P., Kim, E. H., & Mahajan, K. (2024). Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development. Cancers, 16(1), 213. https://doi.org/10.3390/cancers16010213